Lonza announced it has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 billion.
Molex, parent company of Phillips Medisize, has announced that it has signed an agreement to purchase Vectura Group Limited, a leader in inhalation drug device design and formulation.
MSD and Curon have announced that they have entered into a definitive agreement under which MSD has agreed to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases.
Within the new group of companies, Konapharma now complements the services of packaging company Allpack and Rhenochem, a family-owned company with decades of extensive experience and expertise in the global pharmaceutical industry.
Cycle Pharmaceuticals a rapidly growing pharmaceutical company focused on treatments for the underserved rare disease patient community, have confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc.
Johnson & Johnson have announced that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million.
Novo Holdings will acquire an approximately 60% controlling stake in Singe Use Support, alongside the two company founders who will each retain 10% and Danaher which will retain 20% of the share capital.
Cormica, has completed the seven-figure purchase of TPM Laboratories (TPM) in New Jersey. Cormica, backed by Limerston Capital, is focused on strategically expanding its capabilities across the U.S and Europe.
Kühne Holding AG has entered into a definitive agreement to acquire pharma contract development and manufacturing organisation Aenova Group from leading international investment firm BC Partners.
